BridgeBio is substantially advanced the course of an innovative treatment for cardiac amyloidosis, employing the investigational drug. Early patient results suggests significant benefits for patients suffering from a debilitating disease. The emphasis underscores BridgeBio's focus to managing unmet website patient needs in this heart disease field.